The researchers suggest that based on their findings, choice of agent should be guided primarily by adverse effects. According to a commentary, choosing an antipsychotic based on adverse effects is not simple because there are many (extrapyramidal symptoms, akathisia, sedation, weight gain, etc) and they differ notably in frequency and severity between drugs. It adds that this decision should not really be made by the prescriber as patients have the most relevant views of how well they are likely to tolerate given side-effects. It adds that although allowing patients to make informed choices is recommended by NICE, this practice is poorly researched in terms of outcomes and feasibility. It suggests that if patients were initially given the chance to contribute to drug choice, they would be more willing to return to prescribers to ask for a change rather than simply abandoning treatment. It refers to a study that has shown when this approach is included in a wider package of care, outcomes, such as quality of life and staying in contact with services, are improved.